Document:

EXHIBIT 10.36

                                                               February 16, 2000

                  AGREEMENT dated this 16th day of February, 2000 by and between
ADVANCED VIRAL RESEARCH CORP., a Delaware corporation (the "Company"), with
offices at 200 Corporate Boulevard South, Yonkers, New York 10701 and each of
those persons, severally and not jointly, listed as a purchaser on the Schedule
of purchasers attached as Exhibit B hereto. Such persons are hereafter
collectively referred to as the "Purchasers" and each individually as a
"Purchaser".

                                   ARTICLE 1.
                        AUTHORIZATION OF THE SECURITIES
                        -------------------------------

         The Company represents that it has taken all corporate action necessary
to authorize the issuance and sale of 13,636,357 shares of Common Stock of the
Company, par value $.00001 per share ("Common Stock") and warrants to purchase
an aggregate of 5,454,544 shares of Common Stock of the Company (the
"Warrants"). The Common Stock and the Warrants (collectively, the "Securities")
are to be sold to each Purchaser pursuant to this Agreement. For purposes of
this Agreement the term "Shares" shall mean the shares of Common Stock purchased
hereunder and the shares of Common Stock which may be issued from time to time
pursuant to the exercise of the Warrants.

                                   ARTICLE 2.
                  SALE AND PURCHASE OF THE SECURITIES; CLOSING
                  --------------------------------------------

         2.1.Sale and Purchase of the Securities . Subject to the terms and
conditions hereof and in reliance on the representations and warranties
contained herein, or made pursuant hereto, the Company will issue and sell to
each Purchaser as more particularly referred to below, and each Purchaser will
purchase from the Company, on the Closing Date specified in Section 2.2, the
Securities for the purchase price set forth next to the name of such Purchaser
on Exhibit B, at an aggregate purchase price for all Purchasers of $3,000,000
(the "Aggregate Purchase Price").

         2.2. Closing.

                   (a) The closing of the purchase and sale of the Securities
(the "Closing") shall be deemed to occur when this Agreement has been executed
by both the Company and Purchaser and the Company has received payment for the
Securities. The date on which this occurs is herein called the "Closing Date."

                  (b) On the Closing Date there will be delivered to each
Purchaser (i) the shares of Common stock indicated on Exhibit B registered in
its name and (ii) warrant certificates in the forms of Exhibits A-1 and A-2
registered in such name representing the right to purchase the number of shares
of Common Stock set forth therein. The foregoing Securities shall be delivered
by the Company, against delivery by the Purchasers to the Company of an
unendorsed certified or

<PAGE>

official bank check drawn upon or issued by a bank which is a member of the New
York Clearinghouse for banks (or wire transfer) for the aggregate purchase price
to be paid by such Purchaser) payable to the order of the Company.

                                   ARTICLE 3.
                   PURCHASERS REPRESENTATIONS AND WARRANTIES
                   -----------------------------------------

         Each Purchaser represents and warrants to and covenants with the
Company that:

         3.1. Qualified Buyer. Purchaser is an "accredited investor" within the
meaning of Rule 501 of Regulation D promulgated under the Securities Act of
1933, as amended (the "Securities Act"). Either alone or together with the
advice of a representative, Purchaser is sophisticated and experienced in
making, and is qualified to make, decisions with respect to investments in
securities presenting an investment decision like that involved in the purchase
of the Securities, including investments in securities issued by the Company.
Purchaser has requested, received, reviewed and considered, either alone or with
a representative, all information Purchaser deems relevant in making an informed
decision to purchase the Securities.

          3.2. Compliance With Laws. Purchaser will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to
buy, purchase or otherwise acquire or take a pledge of) any of the Securities
purchased hereunder except in compliance with the Securities Act, applicable
blue sky laws, and the rules and regulations promulgated thereunder.

         3.3.Qualified Investor Questionnaire. Purchaser has completed or caused
to be completed the Confidential U.S. Purchaser Questionnaire For Individuals,
attached hereto as Appendix I. The answers thereto are true and correct as of
the date hereof and will be true and correct as of the Closing (provided that
Purchaser shall be entitled to update such information by providing notice
thereof to the Company prior to the Closing).

         3.4. Capacity to Enter Into Agreement. Purchaser has full right, power,
authority and capacity to enter into this Agreement and to consummate the
transactions contemplated hereby. Upon the execution and delivery of this
Agreement by Purchaser, this Agreement shall constitute a valid and binding
obligation, enforceable in accordance with its terms, except (a) as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting creditors' and contracting
parties' rights generally, and (b) as limited by equitable principles generally.

         3.5. Ownership in the Company. Upon completion of the transaction or
upon exercise of any Warrant, Purchaser will not directly or beneficially own
more than 4.9% of the Common Stock of the Company.

         3.6.Independent Investigation . In electing to purchase the Securities
hereunder, Purchaser has relied solely upon the representations and warranties
of the Company set forth in this Agreement and on independent investigation made
by Purchaser and his representatives, if any, and Purchaser has not been given
any oral or written representations or assurance from the Company or any
representative of the Company other than as set forth in this Agreement or in a
document

<PAGE>

executed by a duly authorized representative of the Company making reference to
this Agreement.

         3.7. No Government Recommendation or Approval. Purchaser understands
that no United States federal or state agency, or similar agency of any other
country, has passed upon or made any recommendation or endorsement of the
Company, this transaction or the purchase of the Securities.

         3.8. Further Limitations on Disposition. Without in any way limiting
the representations set forth above, Purchaser agrees not to make any
disposition of all or any portion of the Securities (or the Shares issuable upon
the exercise of the Warrants) unless and until (a) there is then in effect a
registration statement under the Securities Act covering such proposed
disposition and such disposition is made in accordance with such registration
statement, or (b) the disposition is made pursuant to an available exemption
from the registration requirements of the Securities Act and in the case of
clause (b) Purchaser shall have furnished the Company with an opinion of
counsel, reasonably satisfactory to the Company, that such disposition will not
violate any of the securities laws of the United States.

         3.9. Legal Representation. Purchaser has had the opportunity to be
represented in this transaction by counsel of his own choice and has been so
advised by counsel for the Company.

         3.10 Separate Purchasers. Each Purchaser is a separate investor; no
Purchaser is acting in concert with any other Purchaser or any other person in
connection with the purchase of Securities pursuant to this Agreement.

                                   ARTICLE 4.
                 REPRESENTATIONS AND WARRANTIES OF THE COMPANY
                 ---------------------------------------------

         Other than as provided in the Schedule of Exceptions attached hereto as
Exhibit C, the Company represents and warrants as follows:

         4.1.Organization and Existence, etc. The Company is a corporation duly
organized and validly existing and in good standing under the laws of its
jurisdiction of incorporation, and has all requisite corporate power and
authority to carry on its business as now conducted and proposed to be
conducted; the Company has all requisite corporate power and authority to enter
into this Agreement, to issue the Securities as contemplated herein and to carry
out and perform its obligations under the terms and conditions of this
Agreement. The Company does not own or lease any property or engage in any
activity in any jurisdiction which might require qualification to do business as
a foreign corporation in such jurisdiction and where the failure to so qualify
would have a material adverse effect on the financial condition of the Company
or subject the Company to a material liability. To the extent the Company has
not qualified to do business in such jurisdictions, it has, as of the date
hereof, prepared the necessary applications or documents to be filed with the
appropriate authorities in such jurisdictions to obtain such qualifications. The
Company has furnished each Purchaser with true, correct and complete copies of
its Certificate of Incorporation, By-laws and all amendments thereto to date.

<PAGE>

         4.2. Authorization. All corporate action on the part of the Company
and the directors and stockholders of the Company necessary for the
authorization, execution, delivery and performance by the Company of this
Agreement and the transactions contemplated herein, and for the authorization,
issuance and delivery of the Securities, has been taken or will have been taken
prior to the Closing.

         4.3. Binding Obligations; No Material Adverse Contracts, etc. This
Agreement is a valid and binding obligation of the Company enforceable in
accordance with its terms. The execution, delivery and performance by the
Company of this Agreement and compliance herewith will not result in any
violation of and will not conflict with, or result in a breach of any of the
terms of, or constitute a default under, any provision of state or Federal law
to which the Company is subject, the Certificate of Incorporation, as amended,
or the By-laws, as amended, of the Company, or any mortgage, indenture,
agreement, instrument, judgment, decree, order, rule or regulation or other
restriction to which the Company is a party or by which it is bound, or, result
in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of
the properties or assets of the Company pursuant to any such term. Except as set
forth herein, or as waived by such stockholder, no stockholder of the Company
has or will have any preemptive rights or rights of first refusal by reason of
the issuance of the Securities.

         4.4. Offering. Subject in part to the truth and accuracy of the
representations made by each Purchaser herein and such Purchaser's compliance
with his covenants set forth in this Agreement, the offer, sale and issuance of
the Securities as contemplated by this Agreement are not subject to the
registration requirements of the Securities Act, and the Company, or anyone
acting on its behalf, will not take any action hereafter that would cause such
registration requirements to be applicable.

         4.5 SEC Reports. (a) The Company has filed with the Securities and
Exchange Commission (the "Commission") all reports ("SEC Reports") required to
be filed by it under the Securities Act of 1934, as amended (the "Exchange
Act"). All of the SEC Reports filed by the Company comply in all material
respects with the requirements of the Exchange Act. None of the SEC Reports
contains as of the respective dates thereof, any untrue statement of a material
fact or omits to state any material fact required to be stated therein or
necessary to make the statements therein not misleading in light of the
circumstances under which they were made. All financial statements contained in
the SEC Reports have been prepared in accordance with generally accepted
accounting principles consistently applied throughout the period indicated
("GAAP"). Each balance sheet presents fairly in accordance with GAAP the
financial position of the Company as of the date of such balance sheet, and each
statement of operations, of stockholders' equity and of cash flows presents
fairly in accordance with GAAP the results of operations, the stockholders'
equity and the cash flows of the Company for the periods then ended.

         (b) No event has occurred since December 31, 1998 requiring the filing
of an SEC Report that has not heretofore been filed.

         (c) The SEC Reports and this Agreement taken together as a whole will
not, as of the Closing Date, contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein, or necessary to
make the statements contained therein, in light of the circumstances under which
they were made, not misleading.

<PAGE>

         4.6 Disclosure. The information heretofore provided and to be provided
pursuant to this Agreement, and each of the agreements, documents, certificates
and writings previously delivered to Purchaser or his representatives, do not
and will not contain any untrue statement of material fact and do not and will
not omit to state a material fact required to be stated herein or therein or
necessary in order to make the statements and writings contained herein and
therein not false or misleading in light of the circumstances under which they
were made .To the knowledge of the Company, there is no fact which materially
adversely affects the business, prospects or condition (financial or otherwise)
of the Company which has not been set forth herein.

                                    ARTICLE V
                        CONDITIONS TO PURCHASERS CLOSING
                        --------------------------------

         Each Purchaser's obligation to purchase the Securities at the Closing
is subject to the fulfillment to such Purchaser's satisfaction on or prior to
the Closing Date of each of the following conditions, any of which may be waived
by such Purchaser:

         5.1. Representations and Warranties Correct. The representations and
warranties in Article IV hereof shall be true and correct in all material
respects when made, and shall be true and correct in all material respects on
the Closing Date with the same force and effect as if they had been made on and
as of the Closing Date.

         5.2. Performance. All covenants, agreements and conditions contained in
this Agreement to be performed or complied with by the Company on or prior to
the Closing Date shall have been performed or complied with by the Company in
all material respects.

         5.3. No Impediments. Neither Purchaser nor the Company shall be subject
to any order, decree or injunction of a court or administrative agency of
competent jurisdiction which would impose any material limitation on Purchaser's
ability to exercise full rights of ownership of the Securities.

         5.4. Other Agreements. The Company shall have issued to Purchaser all
of the Securities.

         5.5. Legal Investment. At the time of the Closing, the purchase of the
Securities to be purchased hereunder shall be legally permitted by all laws and
regulations to which Purchaser and the Company are subject.

         5.6. Proceedings and Other Documents. All corporate and other
proceedings in connection with the transactions contemplated by this Agreement
shall have been taken and Purchaser shall have received such other documents, in
form and substance reasonably satisfactory to Purchaser, as to such other
matters incident to the transaction contemplated hereby as Purchaser may
reasonably request.

<PAGE>

                                   ARTICLE VI
                      CONDITIONS TO CLOSING OF THE COMPANY
                      ------------------------------------

         The Company's obligation to sell the Securities at the Closing is
subject to the fulfillment to its satisfaction on or prior to the Closing Date
of each of the following conditions:

         6.1. Representations. The representations made by each Purchaser in
Article III hereof shall be true and correct when made and shall be true and
correct on the Closing Date.

         6.2. Legal Investment. At the time of the Closing, the offer, sale and
purchase of the Securities shall be legally permitted by all laws and
regulations to which the Purchasers and the Company are subject.

         6.3. Payment of Purchase Price. The Company shall have received payment
in full of the Aggregate Purchase Price.

                                  ARTICLE VII
                      AFFIRMATIVE COVENANTS AND INDEMNITY
                      -----------------------------------

         The Purchasers and the Company hereby covenant and agree as follows:

         7.1. Further Assurances. From time to time the Company shall execute
and deliver to each Purchaser and each Purchaser shall execute and deliver to
the Company such other instruments, certificates, agreements and documents and
take such other action and do all other things as may be reasonably requested by
the other party in order to implement or effectuate the terms and provisions of
this Agreement and any of the Securities.

         7.2.     Registration Rights.
                  -------------------

                  (a) The Company shall use its best efforts to file on or
before May 31, 2000, a registration statement (the "Registration Statement")
with the Commission, on such form as the Company deems to be appropriate, to
register the Shares under the Securities Act. The Company shall thereafter use
its best efforts to cause the Registration Statement to be declared effective by
the Commission.

                  (b) Each Purchaser shall furnish to the Company such
information as the Company shall reasonably request in writing and as shall be
required in connection with the registration.

         7.3.    Indemnification.
                 ---------------

                  (a) The Company agrees to indemnify and hold each Purchaser
harmless from and against any losses, claims, damages or liabilities to which
such Purchaser may become subject (under the Securities Act or otherwise)
insofar as such losses, claims, damages or liabilities (or actions or
proceedings in respect thereof) arise out of, or are based upon, any Untrue
Statement (as defined below) on or after the effective date of the Registration
Statement, or arise out of any failure by the Company to fulfill any undertaking
included in the Registration Statement and the Company will

<PAGE>

reimburse such Purchaser any reasonable legal or other expenses reasonably
incurred in investigating, defending or preparing to defend any such action,
proceeding or claim; provided, however, that the Company shall not be liable in
any such case to the extent that such loss, claim, damage or liability arises
out of, or is based upon, an Untrue Statement made in such Registration
Statement in reliance upon and in conformity with written information furnished
to the Company by such Purchaser or on such Purchaser's behalf, specifically for
use in preparation of the Registration Statement, or any statement or omission
in any prospectus that is corrected in any subsequent prospectus that was
delivered prior to the pertinent sale or sales by such Purchaser of his Shares.

                  (b) Each Purchaser agrees to indemnify and hold harmless the
Company and each person, if any, who controls the Company within the meeting of
Section 15 of the Securities Act, each officer of the Company who signs the
Registration Statement and each director of the Company from and against any
losses, claims, damages or liabilities to which the Company or any such officer,
director or controlling person may become subject (under the Securities Act or
otherwise), insofar as such losses, claims, damages or liabilities (or actions
or proceedings in respect thereof) arise out of, or are based upon, any failure
to comply with such Purchaser's representation and warranties hereunder, or any
Untrue Statement contained in the Registration Statement on or after the
effective date thereof if such Untrue Statement was made in reliance upon and in
conformity with written information furnished by such Purchaser or on such
Purchaser's behalf specifically for use in preparation of the Registration
Statement, as the case may be, for any legal or other expenses reasonably
incurred in investigating, defending or preparing to defend any such action,
proceeding or claim; provided, however, that in no event shall such Purchaser's
indemnity exceed the gross proceeds received by Purchaser from the sale of
Shares covered by such Registration Statement.

                  (c) Promptly after receipt by any indemnified person of a
notice of a claim or the beginning of any action in respect of which indemnity
is to be sought against an indemnifying person pursuant to this section, such
indemnified person shall notify the indemnifying person in writing of such claim
or of the commencement of such action, and, subject to the provisions
hereinafter stated, in case any such action shall be brought against an
indemnified person and such indemnifying person shall have been notified
thereof, such indemnifying person shall be entitled to participate therein, and,
to the extent it shall wish, to assume the defense thereof, with counsel
reasonably satisfactory to such indemnified person. After notice from the
indemnifying person to such indemnified person of its election to assume the
defense thereof, such indemnifying person shall not be liable to such
indemnified person for any legal expenses subsequently incurred by such
indemnified person in connection with the defense thereof; provided, however,
that if there exists or shall exist a conflict of interest that would make it
inappropriate, in the opinion of counsel to the indemnified person, for the same
counsel to represent both the indemnified person and such indemnifying person or
any affiliate or associate thereof, the indemnified person shall be entitled to
retain its own counsel at the expense of such indemnifying person; provided
further, however, that no indemnifying person shall be responsible for the fees
and expenses of more than one separate counsel for all indemnified parties.

                  (d) "Untrue Statement" means any untrue statement or alleged
untrue statement, or any omission or alleged omission to state in the
Registration Statement a material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.

<PAGE>

                                  ARTICLE VIII
                       COMPLIANCE WITH THE SECURITIES ACT
                       ----------------------------------

         8.1. Legends. The certificate(s) representing the Securities delivered
to the Purchasers at Closing shall be stamped or otherwise imprinted with a
legend substantially similar the following ( in addition to any other legend
required under applicable state securities laws):

         THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER
THE ACT OR, IN THE OPINION OF COUNSEL OR BASED ON OTHER WRITTEN EVIDENCE IN THE
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER,
SALE OR TRANSFER, PLEDGE, OR HYPOTHECATION IS IN COMPLIANCE THEREWITH.

                                   ARTICLE IX
                                 MISCELLANEOUS
                                 -------------

         9.1. Governing Law. This Agreement and the rights of the parties
hereunder shall be governed in all respects by the laws of the State of New
York.

         9.2. Survival. The representations, warranties, covenants and
agreements made herein shall survive the Closing, for a period of one year from
the date of Closing.

         9.3. Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon
and enforceable by and against, the successors, assigns, heirs, executors and
administrators of the parties hereto; provided, however, that the Company may
not assign its rights hereunder.

         9.4. Entire Agreement. This Agreement (including the Exhibits hereto)
and the other documents delivered pursuant hereto and simultaneously herewith
constitute the full and entire understanding and agreement between the parties
with regard to the subject matter hereof and thereof.

         9.5. Amendment. This Agreement may not be amended, discharged or
terminated without the written consent of each Purchaser and that of the
Company.

         9.6. Notices, etc. All notices, demands or other communications given
hereunder shall be in writing and shall be sufficiently given if delivered
either personally or by a nationally recognized courier service marked for next
business day delivery or sent in a sealed envelope by first class mail, postage
prepaid and either registered or certified, addressed as follows:

<PAGE>

           (a)  if to the Company:        Advanced Viral Research Corp.
                                          200 Corporate Boulevard South
                                          Yonkers, New York  10701
                                          Attention:  Shalom Z. Hirschman, M.D.
                                          President and Chief Executive Officer

           (b) if to Purchaser, to the address set forth on Exhibit B to this
Agreement or to such other address with respect to any party hereto as such
party may from time to time notify (as provided above) the other parties hereto.

Any such notice, demand or communication shall be deemed to have been given (i)
on the date of delivery, if delivered personally, (ii) one business day after
delivery to a nationally recognized overnight courier service, if marked for
next day delivery or (iii) five business days after the date of mailing, if
mailed.

         Copies of any notice, demand or communication given to the Company
shall be delivered to Wolf, Block, Schorr and Solis-Cohen LLP, 250 Park Avenue,
New York, New York, 10177, Attn.: Robert E. Fischer, Esq., or such other address
as may be directed.

         9.7. Delays or Omissions. No delay or omission to exercise any right,
power or remedy accruing to any holder of any Securities upon any breach or
default of the Company under this Agreement shall impair any such right, power
or remedy of such holder nor shall it be construed to be a waiver of any such
breach or default, or an acquiescence, therein, or of or in any similar breach
or default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any holder of any breach or default under this
Agreement, or any waiver on the part of any holder of any provisions or
conditions of this Agreement must be made in writing and shall be effective only
to the extent specifically set forth in such writing. Except as otherwise
provided herein, all remedies, either under this Agreement or by law or
otherwise afforded to any holder, shall be cumulative and not alternative.

         9.8. Severability. In case any provision of this Agreement shall be
invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby.

         9.9. Placement Fee. Each Purchaser hereby represents and warrants to
the Company that he has not retained a finder or broker in connection with the
transactions contemplated by this Agreement. The Company hereby represents and
warrants to each Purchaser that it has not retained a finder or broker in
connection with the transactions contemplated by this Agreement. The Company
agrees to indemnify and to hold each Purchaser harmless of and from any
liability for commission or compensation in the nature of an agent's or broker's
fee to any broker, person or firm claiming to have been retained by Company to
act as a finder or broker in connection with this transaction and the costs and
expenses of defending against such liability or asserted liability. Each
Purchaser agrees to indemnify and to hold the Company harmless of and from any
liability for commission or compensation in the nature of an agent's or broker's
fee to any broker, person or firm claiming to have been retained by or on behalf
of such Purchaser to act as a finder or broker in

<PAGE>

connection with this transaction and the costs and expenses of defending against
such liability or asserted liability.

         9.10. Expenses. Each of the parties shall bear its own expenses and
legal fees incurred on its behalf with respect to the negotiation, execution and
consummation of the transactions contemplated by this Agreement.

         9.11. Litigation. The parties each hereby waive trial by jury in any
action or proceeding of any kind or nature in any court in which an action may
be commenced arising out of this Agreement or by reason of any other cause or
dispute whatsoever between them. The parties hereto agree that the State and
Federal Courts which sit in the State of New York and the County of New York
shall have exclusive jurisdiction to hear and determine any claims or disputes
between the Company and such holders, pertaining directly or indirectly to this
Agreement or to any matter arising therefrom. The parties each expressly submit
and consent in advance to such jurisdiction in any action or proceeding
commenced in such courts provided that such consent shall not be deemed to be a
waiver of personal service of the summons and complaint, or other process or
papers issued therein. The choice of forum set forth in this Section 9.11 shall
not be deemed to preclude the enforcement of any judgment obtained in such forum
or the taking of any action under this Agreement to enforce same in any
appropriate jurisdiction. The parties each waive any objection based upon forum
non conveniens and any objection to venue of any action instituted hereunder.

         9.12. Titles and Subtitles. The titles of the articles, sections and
subsections of this Agreement are for convenience of reference only and are not
to be considered in construing this Agreement.

         9.13. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, but all of which together
shall constitute one instrument.

         If a Purchaser is in agreement with the foregoing, such Purchaser
should sign where indicated below and thereupon this letter shall become a
binding agreement between such Purchaser and the Company.

                                    ADVANCED VIRAL RESEARCH CORP.

                                    By: /s/ Shalom Z. Hirschman, M.D.
                                        ---------------------------------
                                    Name: Shalom Z. Hirschman, M.D.
                                    Title: President and Chief Executive Officer

AGREED:

/s/ Joseph Fechbach                        /s/ Kevin Sossin
-------------------                        ----------------
Joseph Fechbach                            Kevin Sossin

HARBOR VIEW GROUP, INC.                    /s/ Frederick P. Lutz
                                           ----------------------
                                           Frederick P. Lutz

By: /s/ Lawrence Pomerantz                 /s/ Michael Duong
    -------------------------              ----------------------
    Lawrence Pomerantz                     Michael Duong

<PAGE>

/s/ Myron Weiner                           /s/ Joseph Deglomina
----------------                           --------------------
Myron Weiner                               Joseph Deglomina

/s/ Victor Sherman                         WEDAR BIOTECH CORP.
------------------
Victor Sherman

                                           By: /s/ authorized representative
                                               -----------------------------

/s/ Michael A. Berman                      /s/ Gerry Goodrich
---------------------------                ------------------
Michael A. Berman                          Gerry Goodrich

/s/ John Zimmerman                         /s/ Merry Contillo
--------------------------                 ----------------------------
John Zimmerman                             Merry Contillo

/s/ Russel Kuhn                            /s/ Bice Grobstein
--------------------------                 ----------------------------
Russell Kuhn                               Bice Grobstein

/s/ Steve Levitt                           /s/ Byron Lassin
--------------------------                 ----------------------------
Steve Levitt                               Byron Lassin

CARDINAL COLOR INC.

By: /s/ authorized representative
    --------------------------------EXHIBIT 10.16

                     TERMINATION AGREEMENT

This  Termination Agreement (the "Agreement"), entered  into  and
effective as of July 31, 1999 (the "Effective Date"), is  between
Douglas  E.  Swanson  ("Swanson")  and  Cliffs  Drilling  Company
("CDC").

In  consideration of the mutual obligations set out below and  in
that agreement of the same effective date between Swanson and CDC
and substantially in the form attached as Exhibit "A" hereto (the
"Non-Compete Agreement"), the parties agree as follows:

     1.   As   of   the   Effective  Date  Swanson  tenders   his
          resignation  as President, Chief Executive Officer  and
          Director  of  CDC  and  as a director,  officer  and/or
          employee  of  all direct and indirect subsidiaries  and
          affiliated  companies  of CDC [other  than  R&B  Falcon
          Corporation ("RBF") of which Swanson shall continue  to
          be  a  director], as the case may be, which CDC accepts
          on  its  behalf and on behalf of RBF, such subsidiaries
          and affiliated companies.

     2.   Upon  execution  of this Agreement and subject  to  the
          payment and other obligations of CDC and RBF set out in
          this  Agreement and in the Non-Compete Agreement,  this
          Agreement and the Non-Compete Agreement constitute full
          satisfaction  of  all  obligations  of  CDC  under  and
          pursuant  to  Section  4 of that  Employment  Agreement
          dated  as of December 1, 1998 between Swanson  and  CDC
          (the "Employment Agreement").

     3.   Notwithstanding anything to the contrary  in  (i)  this
          Agreement,  (ii) Section 7 of the Employment Agreement,
          or  (iii) the Non-Compete Agreement, Swanson shall  not
          be  entitled  to, and CDC shall have no  obligation  to
          make  to  Swanson, any Gross-Up Payment (as defined  in
          Section 7 of the Employment Agreement) with respect  to
          any  Excise  Tax  (as  defined  in  Section  7  of  the
          Employment Agreement) imposed on or with respect to the
          stock  options held by Swanson under the  Stock  Option
          Agreements, which are referred to in  Section 4 of  the
          Non-Compete Agreement, provided, however, the remaining
          obligations  of  CDC  in Section 7  of  the  Employment
          Agreement  shall  continue to  be  in  full  force  and
          effect.

     4.   Swanson  shall have the option, exercisable if  at  all
          only  by  written notice to CDC given  within  60  days
          following the Effective Date, to acquire full ownership
          of those certain split dollar insurance policies, being
          Policy  No.  13905796 dated January 1, 1997 and  Policy
          No.  13347465 dated January 1, 1995, each issued by The
          Northwestern  Mutual Life Insurance  Company,  together
          with a release of the collateral assignments granted in
          favor of CDC under and pursuant to the two Split Dollar
          Insurance  Agreements  dated January  1,  1995  between
          Swanson  and  CDC  (the "Insurance  Agreements"),  upon
          payment by Swanson of the Company's Policy Interest (as
          defined  in the Insurance Agreements).  If such  option
          is  exercised and upon  payment of the sum referred  in
          the  preceding sentence by Swanson and release  of  the
          collateral assignments by CDC, neither Swanson nor  the
          Company  shall  thereafter have any obligation  to  the
          other under the Insurance Agreements.

          For  purposes of this Section 4, such notice, if given,
          shall  be  addressed as follows and sent via registered
          or certified mail:

               Cliffs Drilling Company
               901 Threadneedle, Suite 200
               Houston, Texas 77079

               Attention:  Mr. Paul B. Loyd, Jr.

     5.   The Agreement shall be binding upon and shall inure  to
          the   benefit   of   the  parties,   their   respective
          representatives,  agents,  attorneys,  successors   and
          assigns,  and,  in  particular,  without  limiting  the
          generality   of  the  foregoing,  to  CDC's  directors,
          officers   and   employees  and  to  Swanson's   heirs,
          executors,    administrators,   legal   and    personal
          representatives and assigns.

     6.   This  Agreement shall be deemed to be a  contract  made
          under  and governed by, the laws of the State of Texas,
          without reference to principles of conflicts of law.

     7.   This    Agreement   and   the   Non-Compete   Agreement
          constitutes  the complete and entire agreement  between
          the  parties.   Subject to Sections  4,  5  and  7  (as
          modified  by  Section  3  of  this  Agreement)  of  the
          Employment  Agreement,  this Agreement  supersedes  and
          cancels  all  prior or contemporaneous representations,
          promises  or  agreements  between  the  parties.   This
          Agreement  cannot  be  amended or  modified  except  by
          written agreement signed by each of the parties hereto.

     8.   The  provisions of this Agreement are severable.  If  a
          court or other tribunal of competent jurisdiction rules
          any   provision  of  this  Agreement  is   invalid   or
          unenforceable, such ruling will not affect the validity
          or   enforceability  of  any  other  provision  of  the
          Agreement,  and this Agreement shall be  deemed  to  be
          modified  and  amended so as to be enforceable  to  the
          extent permitted by law.

This Agreement is signed in Houston, Texas on July     , 1999.

                              Douglas E. Swanson

                              CLIFFS DRILLING COMPANY

                              By:
                              Its duly authorized
                              officer

                                             EXHIBIT "A"

                           AGREEMENT

This  Agreement (the "Agreement"), entered into and effective  as
of  July  31,  1999 (the "Effective Date"), is among  Douglas  E.
Swanson  ("Swanson"),  Cliffs Drilling Company  ("CDC")  and  R&B
Falcon Corporation ("RBF").

In  consideration  of  the  mutual  obligations  set  out  below,
Swanson, CDC and RBF agree as follows:

     1.   Within  two  business days following the  execution  of
          this Agreement CDC agrees to pay to Swanson a lump  sum
          in   cash,   less  deductions  required  by   law,   of
          $2,587,500.

     2.   From  the  Effective Date and continuing until December
          1,  2001  CDC agrees to provide Swanson and his family,
          at   the  expense  of  CDC,  all  benefits  under   (or
          substantially  equivalent benefits  to)  RBF's  welfare
          benefit   plans,  practices,  policies   and   programs
          (including,  without limitation, medical, prescription,
          dental,  vision, disability, salary continuance,  group
          life  and supplemental group life and accidental  death
          insurance  plans and programs), to the extent generally
          applicable to other RBF executives.

     3.   For a period of three (3) years following the Effective
          Date (the "Restricted Period") Swanson agrees:

          (a)  Not  to  engage  in  Competition  with  CDC.   For
               purposes of this Section 3(a), "Competition" shall
               mean  Swanson  engaging in or  otherwise  being  a
               director,  officer,  employee,  principal,  agent,
               stockholder,  member,  owner  or  partner  of,  or
               permitting his name to be used in connection  with
               the   activities  of  any  corporation  or   other
               business  organization  in the  offshore  contract
               drilling    industry   in   direct   or   indirect
               competition  with CDC, its parent,  subsidiary  or
               affiliated  companies,  but  shall  not   preclude
               Swanson  from being or becoming the registered  or
               beneficial owner of up to five (5%) of  any  class
               of  capital  voting  stock (or  equivalent  voting
               interest)  of  any corporation or  other  business
               organization  in  the offshore  contract  drilling
               industry,  provided Swanson does  not  participate
               actively  in such business until the  end  of  the
               Restricted Period.

          (b)  Not to disclose to any third party not a member of
               the Company Group (as hereinafter defined), its or
               their   legal  counsel  or  independent  auditors,
               Confidential Information (as hereinafter  defined)
               or  Trade Secrets (as hereinafter defined), except
               any  of  the  Confidential  Information  or  Trade
               Secrets  which  shall be or become in  the  public
               domain  other  than by breach by  Swanson  of  his
               obligations set out in this Section 3(b) or  shall
               be  required to be disclosed by applicable laws or
               regulations,   any   judicial  or   administrative
               authority or stock exchange rule or regulation.

               For  purposes  of  this  Section  3(b):   "Company
               Group"  shall  mean  CDC, its parent  corporation,
               subsidiaries  and  affiliates;  "Confidential  In-
               formation"  shall mean (r) internal  policies  and
               procedures,   (s)   financial   information,   (t)
               marketing   strategies,  (u)  secret  discoveries,
               inventions, formulae, designs, methods,  processes
               and  know-how not constituting Trade Secrets,  and
               (v)  other non-public information relating to  the
               Company Group's business, the disclosure of  which
               would  materially  adversely  affect  the  Company
               Group's  business  or  financial  condition;   and
               "Trade Secrets" shall mean all secret discoveries,
               inventions, formulae, designs, methods,  processes
               and  know-how  entitled  to  protection  as  trade
               secrets under the laws of the state of Texas.

     4.        (a)   The  Stock Option Agreements between Swanson
               and   CDC   referred  to  below  are  respectively
               amended:   (i)  to  revise the  number  of  option
               shares  covered  by  each such  agreement  and  to
               revise  the  option exercise price  per  share  to
               reflect  the  adjustments necessary to  take  into
               account the conversion of CDC shares to shares  of
               RBF effected as a result of the merger transaction
               between CDC and RBF concluded December 1,1998, and
               (ii)  to  extend the period of time  within  which
               Swanson   shall  be  entitled  to   exercise   the
               outstanding   stock   options   granted   to   him
               thereunder, notwithstanding the provisions of such
               Stock Option Agreements, as follows:

                                         Option
Date of Agreement    No. of Options   Exercise Price    Period of Time
                                       (per share)      to Exercise

  May 22, 1996          47,600           $  8.24        May 21, 2006
  May 21, 1997          34,000             19.27        May 20, 2007
  May 13, 1998          85,000             29.71        May 12, 2008

          (b)  The Stock Option Agreement between Swanson and RBF
               dated  December 1, 1998 is amended to  remove  the
               restrictions on vesting and extend the  period  of
               time  within  which Swanson shall be  entitled  to
               exercise the outstanding stock options granted  to
               him    thereunder    to    December    1,    2008,
               notwithstanding  the  provisions  of  such   Stock
               Option Agreement.

     5.   The Agreement shall be binding upon and shall inure  to
          the   benefit   of   the  parties,   their   respective
          representatives,  agents,  attorneys,  successors   and
          assigns,  and,  in  particular,  without  limiting  the
          generality  of  the  foregoing,  to  CDC's  and   RBF's
          directors,  officers  and employees  and  to  Swanson's
          heirs,  executors, administrators, legal  and  personal
          representatives and assigns.

     6.   This  Agreement shall be deemed to be a  contract  made
          under  and governed by, the laws of the State of Texas,
          without reference to principles of conflicts of law.

     7.   The  provisions of this Agreement are severable.  If  a
          court or other tribunal of competent jurisdiction rules
          any   provision  of  this  Agreement  is   invalid   or
          unenforceable, such ruling will not affect the validity
          or   enforceability  of  any  other  provision  of  the
          Agreement,  and this Agreement shall be  deemed  to  be
          modified  and  amended so as to be enforceable  to  the
          extent permitted by law.

     This  Agreement is signed in Houston, Texas  on  July      ,
1999.

                              Douglas E. Swanson

                              CLIFFS DRILLING COMPANY

                              By:
                                 Its duly authorized
                                 officer

                              R&B FALCON CORPORATION

                              By:
                                 Its duly authorized
                                 officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00006-of-00352.parquet"}]]